Mortality in older people with diabetes: A review of current research


  • Angus Forbes



Mortality, Diabetes, Older people, Glycaemic control


Older people with diabetes have reduced life expectancy compared to those without diabetes. They also have increased mortality risk. This paper looks at some of the factors that may explain the increased mortality risk in older people. Consideration is given to: comorbidities; polypharmacy and diabetes therapies; glycaemic control and targets; and frailty. The paper considers how we might be able to reduce the mortality hazard for older people, considering the heterogeneous nature of the population.


Download data is not yet available.


Gordon-Dseagu V, Shelton N, Mindell J. Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: Evidence from the Health Survey for England and Scottish Health Survey cohorts. J Diabetes Complications. 2014;28(6):791–7. doi: 10.1016/j.jdiacomp.2014.06.016

Campbell PT, Newton C, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44. doi: 10.2337/dc12-0002

Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41. doi: 10.1056/NEJMoa1008862

Preis S, Hwang S, Coady S, Pencina MJ, D'Agostino RB, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham heart study, 1950 to 2005. Circulation. 2009;119:1728–35. doi: 10.1161/CIRCULATIONAHA.108.829176

Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus magnitude of the evidence from a systematic review and meta-analysis. Br J Diabetes Vasc Dis. 2013;13(4):192–207. doi: 10.1177/1474651413495703

Barnett K, Mcmurdo M, Ogston S, Morris A, Evans J. Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age Ageing. 2006;35:463–8. doi: 10.1093/ageing/afl019

Huang E, Laiteerapong N, Liu J, John P, Moffet H, Karter A. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251–8. doi: 10.1001/jamainternmed.2013.12956

Ioacara S, Guja C, Fica S, Ionescu-Tirgoviste C. The dynamics of life expectancy over the last six decades in elderly people with diabetes. Diabetes Res Clin Pract. 2013;99(2):217–22. doi: 10.1016/j.diabres.2012.10.020

Bethel M, Sloan F, Belsky D, Feinglos M. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167(9):921–7. doi: 10.1001/archinte.167.9.921

Forbes A, Murrells T, Sinclair A. Examining factors associated with excess mortality in older people (age ≥70 years) with diabetes — a 10 year cohort study of older people with and without diabetes. Diabetic Med. 2016.

Tan HH, McAlpine RR, James P, Thompson P, Mcmurdo MET, Morris AD, et al. Diagnosis of type 2 diabetes at an older age — Effect on mortality in men and women. Diabetes Care. 2004;27:2797–9. doi: 10.2337/diacare.27.12.2797

Gatling W, Guzder RN, Turnbull JC, Budd S, Mullee MA. The Poole Diabetes Study: how many cases of type 2 diabetes are diagnosed each year during normal health care in a defined community? Diabetes Res Clin Pract. 2001;53:107–12. doi: 10.1016/S0168-8227(01)00245-5

Laiteerapong N, Iveniuk J, John PM, Laumann EO, Huang ES. Classification of older adults who have diabetes by comorbid conditions, United States, 2005–2006. Prev Chronic Dis. 2012;9:3–8.

Ebbesen J, Buajorder I, Erickson J, Brors O, Coleman S, Katon W, et al. Depression and death in diabetes; 10-year follow-up of all-cause and cause-specific mortality in a diabetic cohort. Psychosomatics. 2013;54(5):428–36. doi: 10.1016/j.psym.2013.02.015

Kimbro LB, Mangione CM, Steers NW, Duru OK, McEwen L, Karter A, et al. Depression and all-cause mortality in persons with diabetes mellitus: are older adults at higher risk? Results from the translating research into action for diabetes study. J Am Geriatr Soc. 2014;62:1017–23. doi: 10.1111/jgs.12833

Laditka SB, Laditka JN. Document active life expectancy of Americans with diabetes: risks of heart disease, obesity, and inactivity. Diabetes Res Clin Pract. 2015;107(1):37–45. doi: 10.1016/j.diabres.2014.10.008

Grembowski D, Ralston JD, Anderson ML. Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with DM: a retrospective 9-year cohort study. Diabetes Res Clin Pract. 2014;106(2):373–82. doi: 10.1016/j.diabres.2014.07.017

Tancredi M, Rosengren A, Svensson A, Kosiborod M, Pivodic A, Gudbjörnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–32. doi: 10.1056/NEJMoa1504347

Wang Y, Negishi T, Negishi K, Marwick TH. Document prediction of heart failure in patients with type 2 diabetes mellitus — a systematic review and meta-analysis. Diabetes Res Clin Prac. 2014;108(1):55–66. doi: 10.1016/j.diabres.2015.01.011

Lam H, Zannad F, White WB, Cannon CP, Cushman WC, Bakris GL, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76. doi: 10.1016/S0140-6736(14)62225-X

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N England J Med. 2015. doi:10.1056/NEJMoa1504720.

Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30:2148–53. doi: 10.2337/dc07-0141

Ebbesen J, Buajorder I, Erickson J, Brors O, Hilberg T, Svaar H, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001;161:2317–23. doi: 10.1001/archinte.161.19.2317

Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039–48. doi: 10.2165/11319530-000000000-00000

Bauer S, Nauck MA. Polypharmacy in people with type 1 and type 2 diabetes is justified by current guidelines — a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems. Diabet Med. 2014;9:1078–85. doi: 10.1111/dme.12497

Bramlage P, Gitt A, Binz C, Krekler M, Deeg E, Tschöpe D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycaemia. Cardiovasc Diabetol. 2012;11:122–9. doi: 10.1186/1475-2840-11-122

Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21(8):511–30. doi: 10.2165/00002512-200421080-00003

Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010;12(1):47–53. 2009. doi: 10.1111/j.1463-1326.2009.01125.x

Currie C, Poole C, Evans E, Petters J, Morgan C. Mortality and other important diabetes related outcomes with insulin vs other antihyperglycaemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):669–7. doi: 10.1210/jc.2012-3042

Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, et al. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality — A retrospective nationwide study. Diabetes Res Clin Pract. 2015;107(1):104–12. doi: 10.1016/j.diabres.2014.09.047

Bannister C, Holden S, Morgan C, Halcox J, Currie, C. Can people with diabetes live longer than those without? A comparision of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, nondiabetic controls. Diabetes Obes Metab. doi:10.1111/dom.12354.

Rockwood K, Howlett SE, MacKnight C, Beattie BL, Bergman H, Hébert R, et al. Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: Report from the Canadian study of health and aging. J Gerontol A Biol Sci Med Sci. 2004;59:1310–7. doi: 10.1093/gerona/59.12.1310

Atiénzar P, Abizanda P, Guppy A, Sinclair AJ. Diabetes and frailty: an emerging issue. Part 2: linking factors. Br J Diabetes Vasc Dis. 2012;12:119–22. doi: 10.1177/1474651412450304

Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. J Am Med Dir Assoc. 2014;15:853–9. doi: 10.1016/j.jamda.2014.10.001

Castro-Rodríguez M, Carnicero JA, Garcia-Garcia FJ, Walter S, Morley JE, Rodríguez-Artalejo F, et al. Frailty as a major factor in the increased risk of death and disability in older people with diabetes. J Am Med Dir Assoc. 2016;17(10):949–55. doi:10.1016/j.jamda.2016.07.013. Epub 2016 Sep 3.

Nilsson G, Hedger P, Ohrvik J. Survival of the fattest: unexpected findings about hyperglycaemia and obesity in a population based study of 75-year-olds. BMJ Open. 2011;1:e000012. doi: 10.1136/bmjopen-2010-000012

Diabetes UK. End of life diabetes care: a strategy document commissioned by Diabetes UK. London: Diabetes UK; 2012. Available from: (accessed 17 May 2016).

Dunning T, Duggan N, Savage S, Martin P. Diabetes and end of life: ethical and methodological issues in gathering evidence to guide care. Scand J Caring Sci. 2013;27(1):203–11. doi: 10.1111/j.1471-6712.2012.01016.x

Sinclair AJ, Rodriguez-Mañas L. Diabetes and frailty: two converging conditions? Can J Diabetes. 2016;40(1):77–83. doi: 10.1016/j.jcjd.2015.09.004

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. doi: 10.1056/NEJMoa0802743

Action in Diabetes and Vascular disease (ADVANCE) Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. doi: 10.1056/NEJMoa0802987

Veteran Affairs Diabetes Trial (VADT), Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39. doi: 10.1056/NEJMoa0808431

Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. doi: 10.1056/NEJMoa052187

Holman R, Paul S, Bethel M, Matthews D, Neil H, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89. doi: 10.1056/NEJMoa0806470

Huang E, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34:1329–36. doi: 10.2337/dc10-2377

Palta P, Huang E, Yeh H-C, Kalyani R, Golden S. Glycated haemoglobin (HbA1c) and mortality in older adults with and without diabetes: results from the national health and nutrition examination surveys (1988–2011). Diabetes Care. 2017;40:453–60. doi: 10.2337/dci16-0042

Du YF, Ou HY, Beverly EA, Chiu CJ. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging 2014;9:1963–80.




How to Cite

Forbes, A. (2017). Mortality in older people with diabetes: A review of current research. International Diabetes Nursing, 14(1), 20–25.



Original Articles

Most read articles by the same author(s)

1 2 > >>